ANIK
Anika Therapeutics Inc
20.40$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -17.5% | -2.5% | -0.4% | -11.9% | -12.4% | -6.0% | -1.5% | +0.9% | +0.4% | -5.7% | +2.3% | |
| – | +4.2% | -2.7% | -2.5% | -12.2% | -16.5% | -9.8% | -3.1% | +2.3% | +1.7% | -9.5% | +6.0% | |
| – | -2.7% | -0.2% | -8.5% | -0.7% | -10.8% | -4.1% | -0.4% | +9.1% | -0.9% | -28.6% | -6.4% | |
| – | -2.7% | -0.2% | -8.5% | -0.7% | -10.8% | -4.1% | -0.4% | +9.1% | -0.9% | -28.6% | -6.4% | |
| – | -24.0% | +21.7% | +5.3% | -16.0% | -16.8% | -6.8% | +9.0% | -7.4% | +6.8% | +8.8% | +12.8% | |
| – | -44.1% | +102.3% | +4.2% | -23.0% | -39.9% | -10.4% | -20.7% | -3.8% | +15.4% | +21.6% | +25.1% | |
| – | +4.4% | -2.2% | -0.7% | +4.2% | -6.9% | +4.2% | +8.5% | -0.1% | +0.0% | -2.0% | -0.8% | |
| – | -96.3% | +66.8% | -7.6% | -22.4% | -19.2% | -8.4% | -27.2% | -0.7% | +0.0% | +0.0% | +0.0% | |
| – | +1.2% | -5.4% | -5.2% | -1.5% | -5.4% | -13.4% | -5.2% | +6.6% | +9.8% | -2.8% | +1.6% | |
| – | +10.7% | -8.4% | -8.2% | -2.4% | -8.6% | -23.2% | -10.2% | +18.7% | +14.8% | -4.3% | +5.6% | |
| – | -11.1% | +16.5% | +7.4% | +0.2% | -16.3% | -2.3% | -3.1% | -5.0% | +19.0% | -5.4% | – | |
| – | -24.9% | +61.8% | -0.3% | -31.9% | -17.5% | -6.1% | -9.6% | -0.8% | +27.7% | +4.9% | -1.6% | |
| – | -21.5% | -1.8% | +0.9% | -14.5% | -14.4% | -3.6% | -0.5% | -0.6% | -2.3% | -6.7% | +2.5% | |
| – | -33.0% | -3.5% | -0.1% | -24.2% | -23.4% | -6.8% | -5.9% | -3.7% | +0.5% | -8.3% | +5.9% | |
| – | +0.1% | +0.3% | +1.0% | -0.5% | -0.3% | -2.9% | +0.5% | +0.4% | +1.7% | -7.8% | -0.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.